: Acadia Pharmaceuticals stock halted for FDA panel to review treatment for hallucinations stemming from Alzheimer's disease psychosis #FinanceUSA #StockMarketNEWS Acadia Pharmaceuticals Inc. said
@stockMarketNEWS 9 Days ago
Acadia Pharmaceuticals stock halted for FDA panel to review treatment for hallucinations stemming from Alzheimer's disease psychosis #FinanceUSA #StockMarketNEWS
Acadia Pharmaceuticals Inc. said Friday its stock will be halted from trading Friday as a U.S. Food and Drug Administration panel meets virtually to discuss a new drug application for a treatment for hallucinations and delusions associated with Alzheimer's disease psychosis. The FDA's Psychopharmacologic Drugs Advisory Committee will review Acadia's Nuplazid at a meeting scheduled for 8:45 a.m. Eastern. About six million people living in the U.S. have Alzheimer's disease, according to the Alzheimer's Association and about 30% of those suffer from psychosis. Acadia shares have fallen 16% in the year to date, while the S&P 500 has fallen 23%.
Munafa USA Munafa India Munafa NSE
More posts by @stockMarketNEWS
: Canada delays rulemaking for cannabis beverages #FinanceUSA #StockMarketNEWS A Health Canada official told MJBiz that the agency does not expect to approve new regulations that would increase the possession
@stockMarketNEWS 9 Days ago
: WWE's Vince McMahon steps aside as CEO during investigation #FinanceUSA #StockMarketNEWS World Wrestling Entertainment Inc. Chief Executive Vince McMahon is stepping aside from that role as well
@stockMarketNEWS 9 Days ago
0 Comments
Sorted by latest first Latest Oldest Best